This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
It doesn't matter if you're a growth, value, income, or momentum-focused investor -- building a successful investment portfolio takes skill, research, and a little bit of luck.
Should You Buy #1 (Strong Buy)-Ranked McKesson (MCK) for Your Portfolio?
McKesson was upgraded to the Zacks Rank #1 list on October 27, 2023. The Zacks Rank is a unique stock-rating model that helps you take advantage of earnings estimate revision trends and provides a way to get into stocks highly sought after by institutional investors.
San Francisco, CA-based McKesson Corporation is a health care services and information technology company. McKesson operates through two segments:
For fiscal 2024, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.05 to $27.21 per share. MCK boasts an average earnings surprise of 8.1%.
Earnings are forecasted to see growth of 4.9% for the current fiscal year, and sales are expected to increase 9.9%.
Even more impressive, MCK has gained in value over the past four weeks, up 3% compared to the S&P 500's loss of 3.6%.
Bottom Line
With a #1 (Strong Buy) ranking, positive trend in earnings estimate revisions, and strong market momentum, McKesson could be just the stock to help your portfolio generate returns that could fund your retirement, your kids' college tuition, or your short- and long-term savings goals.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
